Search results
1 day ago · Background Breast cancer (BC) is a heterogeneous neoplasm characterized by several subtypes. One of the most aggressive with high metastasis rates presents overexpression of the human epidermal growth factor receptor 2 (HER2). A quantitative evaluation of HER2 levels is essential for a correct diagnosis, selection of the most appropriate therapeutic strategy and monitoring the response to therapy. Results In this paper, we propose the synergistic use of SERS and Raman technologies for the ...
May 29, 2024 · e20602 Background: Non-Small Cell Lung Cancer (NSCLC) exhibits a spectrum of molecular alterations that play a crucial role in understanding its heterogeneity and tailoring targeted therapies. Among these alterations, HER2 aberrations have gained significance as potential therapeutic targets. This study aims to explore the diversity of HER2 changes in NSCLC through tissue and liquid biopsies, providing valuable insights into the feasibility and accuracy of either method. Methods: Data from ...
4 days ago · In this regard, nearly 60% of breast cancer patients are diagnosed with HER2-low expression, defined as HER2 1+ or HER2 2+ by immunohistochemistry (IHC) and no gene amplification at reflex molecular testing. 45 DESTINY-Breast04 proved that targeting low level of HER2 with T-DXd was a superior therapeutic approach to standard chemotherapy in patients with unresectable or metastatic HER2-low breast cancer after prior treatment in the metastatic setting. 46 Based on DESTINY-Breast04, T-DXd ...
May 27, 2024 · Invasive breast cancer (BC) is the most common cancer in women worldwide. Human epidermal growth factor receptor 2 (HER2) protein is overexpressed in 20 to 25% of breast carcinomas 1.According to ...
- Ansh Kapil
2 days ago · Finally, we compared the protein structure of a gene when a subtype-specific AS event occurred with the protein structure of a gene when no subtype-specific AS event occurred using PyMOL (v.1.20 ...
Jun 6, 2024 · Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens.
People also ask
How is HER2 protein expression characterized?
What does a HER2 bar represent?
Which QCs-based features enriched the HER2-negative subgroup?
Are Her2 aberrations a potential therapeutic target for non-small cell lung cancer?
Jun 6, 2024 · On completion of this continuing medical education offering, participants will be able to: Explain the role that HER2 overexpression plays in the development of breast cancer. Address the role that HER2 plays as a prognostic marker. Examine the various tests used for measuring HER2 amplification. Discuss the role of trastuzumab in the treatment ...
